Genomma Lab InternacionalB de CV (MEX:LABB) EPS without NRI: MXN1.87 (TTM As of Mar. 2026)


MEX:LABB Genomma Lab Internacional SAB de CV MEX:LABB
66 GF Score
Price MXN15.04
GF Value MXN17.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV EPS without NRI?

Genomma Lab InternacionalB de CV MEX:LABB +2.59% 66 EPS without NRI is MXN1.87 as of Mar. 2026. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 786 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks worse than 59.16% on this metric.

Genomma Lab InternacionalB de CV's earnings per share without non-recurring items for the three months ended in Mar. 2026 was MXN0.59. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1.87.

During the past 12 months, Genomma Lab InternacionalB de CV's average earnings per share (NRI) Growth Rate was -24.50% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 3.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 6.10% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's EPS without NRI or its related term are showing as below:

MEX:LABB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4.5   Med: 16.3   Max: 54
Current: 3.6

During the past 13 years, Genomma Lab InternacionalB de CV's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 54.00% per year. The lowest was -4.50% per year. And the median was 16.30% per year.

MEX:LABB's 3-Year EPS without NRI Growth Rate is ranked worse than
59.16% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs MEX:LABB: 3.60

Genomma Lab InternacionalB de CV's EPS (Diluted) for the three months ended in Mar. 2026 was MXN0.51. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1.64.

Genomma Lab InternacionalB de CV's EPS (Basic) for the three months ended in Mar. 2026 was MXN0.51. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1.64.


Genomma Lab InternacionalB de CV  (MEX:LABB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Genomma Lab InternacionalB de CV EPS without NRI Related Terms


Genomma Lab InternacionalB de CV EPS without NRI Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV EPS without NRI Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.53 1.64 1.31 2.41 1.82

Genomma Lab InternacionalB de CV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.41 0.50 0.37 0.59

MEX:LABB vs ZTS, UTHR, VTRS: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's PE Ratio without NRI falls into.


MEX:LABB
66GF Score
Genomma Lab Internacional SAB de CV MEX:LABB
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomma Lab InternacionalB de CV EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of MXN1.87 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a EPS without NRI of MXN1.87 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Genomma Lab InternacionalB de CV and its competitors. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #465 out of 786 companies in the Drug Manufacturers industry, placing it in the top 59.2%.
Is Genomma Lab InternacionalB de CV's EPS without NRI too high?
Genomma Lab InternacionalB de CV's current EPS without NRI is MXN1.87. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #465 out of 786 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #465 out of 786 companies for EPS without NRI. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current EPS without NRI is MXN1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current EPS without NRI is MXN1.87. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current EPS without NRI is MXN1.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for MEX:LABB:

  • EPS without NRI: MXN1.87
  • GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USAGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score

Get the complete analysis for MEX:LABB

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.04
Price
MXN17.64
GF Value